Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients.

Autor: Wang X; Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642 USA., Ring BZ; Institute for Genomic and Personalized Medicine, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China., Seitz RS; Insight Genetics Inc., Nashville, TN USA., Ross DT; CardioDx, Inc., Redwood City, CA USA., Woolf K; Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642 USA., Beck RA; Conversant Biologics, Huntsville, AL USA., Hicks DG; Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642 USA., Yeh S; Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642 USA.
Jazyk: angličtina
Zdroj: BMC clinical pathology [BMC Clin Pathol] 2015 Dec 09; Vol. 15, pp. 21. Date of Electronic Publication: 2015 Dec 09 (Print Publication: 2015).
DOI: 10.1186/s12907-015-0021-5
Abstrakt: Background: The role of vitamin E in breast cancer prevention and treatment has been widely investigated, and the different tocopherols that comprise this nutrient have been shown to have divergent associations with cancer outcome. Our previous studies have shown that α-Tocopherol-associated protein (TAP), a vitamin E binding protein, may function as a tumor suppressor-like factor in breast carcinogenesis. The current study addresses the association of TAP expression with breast cancer clinical outcomes.
Methods: Immunohistochemical stain for TAP was applied to a tissue microarray from a breast cancer cohort consisting of 271 patients with a median follow-up time of 5.2 years. The expression of TAP in tumor cells was compared with patient's clinical outcome at 5 years after diagnosis. The potential role of TAP in predicting outcome was also assessed in clinically relevant subsets of the cohort. In addition, we compared TAP expression and Oncotype DX scores in an independent breast cancer cohort consisting of 71 cases.
Results: We demonstrate that the expression of TAP was differentially expressed within the breast cancer cohort, and that ER+/PR ± tumors were more likely to exhibit TAP expression. TAP expression was associated with an overall lower recurrence rate and a better 5-year survival rate. This association was primarily in patients with ER+ tumors; exploratory analysis showed that this association was strongest in patients with node-positive tumors and was independent of stage and treatment with chemotherapy. TAP expression in ER/PR negative or triple negative tumors had no association with clinical outcome. In addition, we did not observe an association between TAP expression and Oncotype DX recurrence score.
Conclusions: The significant positive association we found for α-Tocopherol-associated protein with outcome in breast cancer may help to better define and explain studies addressing α-tocopherol's association with cancer risk and outcome. Additionally, further studies to validate and extend these findings may allow TAP to serve as a breast-specific prognostic marker in breast cancer patients, especially in those patients with ER+ tumors.
Databáze: MEDLINE
Externí odkaz: